The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Opioid Induced Constipation Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation Drugs market size is expected to reach US$ 3490.4 million by 2029, growing at a CAGR of 4.6% from 2023 to 2029. The market is mainly driven by the significant applications of Opioid Induced Constipation Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Opioid Induced Constipation Drugs market. Lubiprostone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Methyl Naltrexone Bromide segment is estimated at % CAGR for the next seven-year period.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioid Induced Constipation Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioid Induced Constipation Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioid Induced Constipation Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioid Induced Constipation Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioid Induced Constipation Drugs covered in this report include Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi & Co., Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma and S.L.A. Pharma AG, etc.
The global Opioid Induced Constipation Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Global Opioid Induced Constipation Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioid Induced Constipation Drugs market, Segment by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Global Opioid Induced Constipation Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Opioid Induced Constipation Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Opioid Induced Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
The global Opioid Induced Constipation Drugs market size is expected to reach US$ 3490.4 million by 2029, growing at a CAGR of 4.6% from 2023 to 2029. The market is mainly driven by the significant applications of Opioid Induced Constipation Drugs in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Opioid Induced Constipation Drugs market. Lubiprostone, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Methyl Naltrexone Bromide segment is estimated at % CAGR for the next seven-year period.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Opioid Induced Constipation Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Opioid Induced Constipation Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Opioid Induced Constipation Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Opioid Induced Constipation Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Opioid Induced Constipation Drugs covered in this report include Ironwood Pharmaceuticals Inc, Daiichi Sankyo Co Ltd, Pfizer, Progenics Pharmaceuticals Inc, Shionogi & Co., Ltd, Allergan Plc, Nektar Therapeutics, Purdue Pharma and S.L.A. Pharma AG, etc.
The global Opioid Induced Constipation Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Ironwood Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Pfizer
Progenics Pharmaceuticals Inc
Shionogi & Co., Ltd
Allergan Plc
Nektar Therapeutics
Purdue Pharma
S.L.A. Pharma AG
Mundipharma International Limited
Ono Pharmaceutical Co., Ltd
Takeda Pharmaceutical Company Limited
Theravance Biopharma Inc
Bausch Health
Cosmo Pharmaceuticals SA
Daewoong Pharmaceutical
C.B. Fleet Company
Sucampo Pharmaceuticals
Global Opioid Induced Constipation Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Opioid Induced Constipation Drugs market, Segment by Type:
Lubiprostone
Methyl Naltrexone Bromide
Naldemedine
Alvimopan
Others
Global Opioid Induced Constipation Drugs market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Opioid Induced Constipation Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Opioid Induced Constipation Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Opioid Induced Constipation Drugs Market Overview
1.1 Opioid Induced Constipation Drugs Product Overview
1.2 Opioid Induced Constipation Drugs Market Segment by Type
1.2.1 Lubiprostone
1.2.2 Methyl Naltrexone Bromide
1.2.3 Naldemedine
1.2.4 Alvimopan
1.2.5 Others
1.3 Global Opioid Induced Constipation Drugs Market Size by Type
1.3.1 Global Opioid Induced Constipation Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Opioid Induced Constipation Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Opioid Induced Constipation Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Opioid Induced Constipation Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Opioid Induced Constipation Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Opioid Induced Constipation Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Opioid Induced Constipation Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Opioid Induced Constipation Drugs Sales Breakdown by Type (2018-2023)
2 Global Opioid Induced Constipation Drugs Market Competition by Company
2.1 Global Top Players by Opioid Induced Constipation Drugs Sales (2018-2023)
2.2 Global Top Players by Opioid Induced Constipation Drugs Revenue (2018-2023)
2.3 Global Top Players by Opioid Induced Constipation Drugs Price (2018-2023)
2.4 Global Top Manufacturers Opioid Induced Constipation Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Opioid Induced Constipation Drugs Market Competitive Situation and Trends
2.5.1 Opioid Induced Constipation Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Opioid Induced Constipation Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Opioid Induced Constipation Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Opioid Induced Constipation Drugs Market
2.8 Key Manufacturers Opioid Induced Constipation Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Opioid Induced Constipation Drugs Status and Outlook by Region
3.1 Global Opioid Induced Constipation Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Opioid Induced Constipation Drugs Historic Market Size by Region
3.2.1 Global Opioid Induced Constipation Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Opioid Induced Constipation Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Opioid Induced Constipation Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Opioid Induced Constipation Drugs Forecasted Market Size by Region
3.3.1 Global Opioid Induced Constipation Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Opioid Induced Constipation Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Opioid Induced Constipation Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Opioid Induced Constipation Drugs by Application
4.1 Opioid Induced Constipation Drugs Market Segment by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Online Pharmacies
4.2 Global Opioid Induced Constipation Drugs Market Size by Application
4.2.1 Global Opioid Induced Constipation Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Opioid Induced Constipation Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Opioid Induced Constipation Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Opioid Induced Constipation Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Opioid Induced Constipation Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Opioid Induced Constipation Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Opioid Induced Constipation Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Opioid Induced Constipation Drugs Sales Breakdown by Application (2018-2023)
5 North America Opioid Induced Constipation Drugs by Country
5.1 North America Opioid Induced Constipation Drugs Historic Market Size by Country
5.1.1 North America Opioid Induced Constipation Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Opioid Induced Constipation Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Opioid Induced Constipation Drugs Sales in Value by Country (2018-2023)
5.2 North America Opioid Induced Constipation Drugs Forecasted Market Size by Country
5.2.1 North America Opioid Induced Constipation Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Opioid Induced Constipation Drugs Sales in Value by Country (2024-2029)
6 Europe Opioid Induced Constipation Drugs by Country
6.1 Europe Opioid Induced Constipation Drugs Historic Market Size by Country
6.1.1 Europe Opioid Induced Constipation Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Opioid Induced Constipation Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Opioid Induced Constipation Drugs Sales in Value by Country (2018-2023)
6.2 Europe Opioid Induced Constipation Drugs Forecasted Market Size by Country
6.2.1 Europe Opioid Induced Constipation Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Opioid Induced Constipation Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Opioid Induced Constipation Drugs by Region
7.1 Asia-Pacific Opioid Induced Constipation Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Opioid Induced Constipation Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Opioid Induced Constipation Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Opioid Induced Constipation Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Opioid Induced Constipation Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Opioid Induced Constipation Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Opioid Induced Constipation Drugs Sales in Value by Region (2024-2029)
8 Latin America Opioid Induced Constipation Drugs by Country
8.1 Latin America Opioid Induced Constipation Drugs Historic Market Size by Country
8.1.1 Latin America Opioid Induced Constipation Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Opioid Induced Constipation Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Opioid Induced Constipation Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Opioid Induced Constipation Drugs Forecasted Market Size by Country
8.2.1 Latin America Opioid Induced Constipation Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Opioid Induced Constipation Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Opioid Induced Constipation Drugs by Country
9.1 Middle East and Africa Opioid Induced Constipation Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Opioid Induced Constipation Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Opioid Induced Constipation Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Opioid Induced Constipation Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Opioid Induced Constipation Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Opioid Induced Constipation Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Opioid Induced Constipation Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Ironwood Pharmaceuticals Inc
10.1.1 Ironwood Pharmaceuticals Inc Company Information
10.1.2 Ironwood Pharmaceuticals Inc Introduction and Business Overview
10.1.3 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Ironwood Pharmaceuticals Inc Opioid Induced Constipation Drugs Products Offered
10.1.5 Ironwood Pharmaceuticals Inc Recent Development
10.2 Daiichi Sankyo Co Ltd
10.2.1 Daiichi Sankyo Co Ltd Company Information
10.2.2 Daiichi Sankyo Co Ltd Introduction and Business Overview
10.2.3 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Daiichi Sankyo Co Ltd Opioid Induced Constipation Drugs Products Offered
10.2.5 Daiichi Sankyo Co Ltd Recent Development
10.3 Pfizer
10.3.1 Pfizer Company Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Pfizer Opioid Induced Constipation Drugs Products Offered
10.3.5 Pfizer Recent Development
10.4 Progenics Pharmaceuticals Inc
10.4.1 Progenics Pharmaceuticals Inc Company Information
10.4.2 Progenics Pharmaceuticals Inc Introduction and Business Overview
10.4.3 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Progenics Pharmaceuticals Inc Opioid Induced Constipation Drugs Products Offered
10.4.5 Progenics Pharmaceuticals Inc Recent Development
10.5 Shionogi & Co., Ltd
10.5.1 Shionogi & Co., Ltd Company Information
10.5.2 Shionogi & Co., Ltd Introduction and Business Overview
10.5.3 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Shionogi & Co., Ltd Opioid Induced Constipation Drugs Products Offered
10.5.5 Shionogi & Co., Ltd Recent Development
10.6 Allergan Plc
10.6.1 Allergan Plc Company Information
10.6.2 Allergan Plc Introduction and Business Overview
10.6.3 Allergan Plc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Allergan Plc Opioid Induced Constipation Drugs Products Offered
10.6.5 Allergan Plc Recent Development
10.7 Nektar Therapeutics
10.7.1 Nektar Therapeutics Company Information
10.7.2 Nektar Therapeutics Introduction and Business Overview
10.7.3 Nektar Therapeutics Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Nektar Therapeutics Opioid Induced Constipation Drugs Products Offered
10.7.5 Nektar Therapeutics Recent Development
10.8 Purdue Pharma
10.8.1 Purdue Pharma Company Information
10.8.2 Purdue Pharma Introduction and Business Overview
10.8.3 Purdue Pharma Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Purdue Pharma Opioid Induced Constipation Drugs Products Offered
10.8.5 Purdue Pharma Recent Development
10.9 S.L.A. Pharma AG
10.9.1 S.L.A. Pharma AG Company Information
10.9.2 S.L.A. Pharma AG Introduction and Business Overview
10.9.3 S.L.A. Pharma AG Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 S.L.A. Pharma AG Opioid Induced Constipation Drugs Products Offered
10.9.5 S.L.A. Pharma AG Recent Development
10.10 Mundipharma International Limited
10.10.1 Mundipharma International Limited Company Information
10.10.2 Mundipharma International Limited Introduction and Business Overview
10.10.3 Mundipharma International Limited Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Mundipharma International Limited Opioid Induced Constipation Drugs Products Offered
10.10.5 Mundipharma International Limited Recent Development
10.11 Ono Pharmaceutical Co., Ltd
10.11.1 Ono Pharmaceutical Co., Ltd Company Information
10.11.2 Ono Pharmaceutical Co., Ltd Introduction and Business Overview
10.11.3 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Ono Pharmaceutical Co., Ltd Opioid Induced Constipation Drugs Products Offered
10.11.5 Ono Pharmaceutical Co., Ltd Recent Development
10.12 Takeda Pharmaceutical Company Limited
10.12.1 Takeda Pharmaceutical Company Limited Company Information
10.12.2 Takeda Pharmaceutical Company Limited Introduction and Business Overview
10.12.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation Drugs Products Offered
10.12.5 Takeda Pharmaceutical Company Limited Recent Development
10.13 Theravance Biopharma Inc
10.13.1 Theravance Biopharma Inc Company Information
10.13.2 Theravance Biopharma Inc Introduction and Business Overview
10.13.3 Theravance Biopharma Inc Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Theravance Biopharma Inc Opioid Induced Constipation Drugs Products Offered
10.13.5 Theravance Biopharma Inc Recent Development
10.14 Bausch Health
10.14.1 Bausch Health Company Information
10.14.2 Bausch Health Introduction and Business Overview
10.14.3 Bausch Health Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Bausch Health Opioid Induced Constipation Drugs Products Offered
10.14.5 Bausch Health Recent Development
10.15 Cosmo Pharmaceuticals SA
10.15.1 Cosmo Pharmaceuticals SA Company Information
10.15.2 Cosmo Pharmaceuticals SA Introduction and Business Overview
10.15.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation Drugs Products Offered
10.15.5 Cosmo Pharmaceuticals SA Recent Development
10.16 Daewoong Pharmaceutical
10.16.1 Daewoong Pharmaceutical Company Information
10.16.2 Daewoong Pharmaceutical Introduction and Business Overview
10.16.3 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Daewoong Pharmaceutical Opioid Induced Constipation Drugs Products Offered
10.16.5 Daewoong Pharmaceutical Recent Development
10.17 C.B. Fleet Company
10.17.1 C.B. Fleet Company Company Information
10.17.2 C.B. Fleet Company Introduction and Business Overview
10.17.3 C.B. Fleet Company Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.17.4 C.B. Fleet Company Opioid Induced Constipation Drugs Products Offered
10.17.5 C.B. Fleet Company Recent Development
10.18 Sucampo Pharmaceuticals
10.18.1 Sucampo Pharmaceuticals Company Information
10.18.2 Sucampo Pharmaceuticals Introduction and Business Overview
10.18.3 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Sales, Revenue and Gross Margin (2018-2023)
10.18.4 Sucampo Pharmaceuticals Opioid Induced Constipation Drugs Products Offered
10.18.5 Sucampo Pharmaceuticals Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Opioid Induced Constipation Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Opioid Induced Constipation Drugs Industrial Chain Analysis
11.4 Opioid Induced Constipation Drugs Market Dynamics
11.4.1 Opioid Induced Constipation Drugs Industry Trends
11.4.2 Opioid Induced Constipation Drugs Market Drivers
11.4.3 Opioid Induced Constipation Drugs Market Challenges
11.4.4 Opioid Induced Constipation Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Opioid Induced Constipation Drugs Distributors
12.3 Opioid Induced Constipation Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
